The global pharmaceutical CRO market size accounted for USD 47.89 billion in 2025 and is predicted to surpass around USD 91.20 billion by 2034, representing a solid CAGR of 7.42% between 2025 and 2034. The Asia Pacific pharmaceutical CRO market size is evaluated at USD 22.51 billion in 2025 and is expected to grow at a solid CAGR of 7.54% during the forecast year. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmaceutical CRO Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmaceutical CRO Market, by Type
8.1.1. Drug Discovery
8.1.1.1. Market Revenue and Forecast
8.1.2. Pre-Clinical
8.1.2.1. Market Revenue and Forecast
8.1.3. Clinical
8.1.3.1. Market Revenue and Forecast
9.1. Pharmaceutical CRO Market, by Molecule Type
9.1.1. Small Molecules
9.1.1.1. Market Revenue and Forecast
9.1.2. Large Molecules
9.1.2.1. Market Revenue and Forecast
10.1. Pharmaceutical CRO Market, by Service
10.1.1. Project Management/Clinical Supply Management
10.1.1.1. Market Revenue and Forecast
10.1.2. Data Management
10.1.2.1. Market Revenue and Forecast
10.1.3. Regulatory/Medical Affairs
10.1.3.1. Market Revenue and Forecast
10.1.4. Medical Writing
10.1.4.1. Market Revenue and Forecast
10.1.5. Clinical Monitoring
10.1.5.1. Market Revenue and Forecast
10.1.6. Quality Management/ Assurance
10.1.6.1. Market Revenue and Forecast
10.1.7. Biostatistics
10.1.7.1. Market Revenue and Forecast
10.1.8. Investigator Payments
10.1.8.1. Market Revenue and Forecast
10.1.9. Laboratory
10.1.9.1. Market Revenue and Forecast
10.1.10. Patient And Site Recruitment
10.1.10.1. Market Revenue and Forecast
10.1.11. Technology
10.1.11.1. Market Revenue and Forecast
10.1.12. Others
10.1.12.1. Market Revenue and Forecast
11.1. Pharmaceutical CRO Market, by Therapeutic Areas
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Cns Disorders
11.1.2.1. Market Revenue and Forecast
11.1.3. Infectious Diseases
11.1.3.1. Market Revenue and Forecast
11.1.4. Immunological Disorders
11.1.4.1. Market Revenue and Forecast
11.1.5. Cardiovascular Disease
11.1.5.1. Market Revenue and Forecast
11.1.6. Respiratory Diseases
11.1.6.1. Market Revenue and Forecast
11.1.7. Diabetes
11.1.7.1. Market Revenue and Forecast
11.1.8. Ophthalmology
11.1.8.1. Market Revenue and Forecast
11.1.9. Pain Management
11.1.9.1. Market Revenue and Forecast
11.1.10. Others
11.1.10.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type
12.1.2. Market Revenue and Forecast, by Molecule Type
12.1.3. Market Revenue and Forecast, by Service
12.1.4. Market Revenue and Forecast, by Therapeutic Areas
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type
12.1.5.2. Market Revenue and Forecast, by Molecule Type
12.1.5.3. Market Revenue and Forecast, by Service
12.1.5.4. Market Revenue and Forecast, by Therapeutic Areas
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type
12.1.6.2. Market Revenue and Forecast, by Molecule Type
12.1.6.3. Market Revenue and Forecast, by Service
12.1.6.4. Market Revenue and Forecast, by Therapeutic Areas
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type
12.2.2. Market Revenue and Forecast, by Molecule Type
12.2.3. Market Revenue and Forecast, by Service
12.2.4. Market Revenue and Forecast, by Therapeutic Areas
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type
12.2.5.2. Market Revenue and Forecast, by Molecule Type
12.2.5.3. Market Revenue and Forecast, by Service
12.2.5.4. Market Revenue and Forecast, by Therapeutic Areas
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type
12.2.6.2. Market Revenue and Forecast, by Molecule Type
12.2.6.3. Market Revenue and Forecast, by Service
12.2.6.4. Market Revenue and Forecast, by Therapeutic Areas
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type
12.2.7.2. Market Revenue and Forecast, by Molecule Type
12.2.7.3. Market Revenue and Forecast, by Service
12.2.7.4. Market Revenue and Forecast, by Therapeutic Areas
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type
12.2.8.2. Market Revenue and Forecast, by Molecule Type
12.2.8.3. Market Revenue and Forecast, by Service
12.2.8.4. Market Revenue and Forecast, by Therapeutic Areas
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type
12.3.2. Market Revenue and Forecast, by Molecule Type
12.3.3. Market Revenue and Forecast, by Service
12.3.4. Market Revenue and Forecast, by Therapeutic Areas
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type
12.3.5.2. Market Revenue and Forecast, by Molecule Type
12.3.5.3. Market Revenue and Forecast, by Service
12.3.5.4. Market Revenue and Forecast, by Therapeutic Areas
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type
12.3.6.2. Market Revenue and Forecast, by Molecule Type
12.3.6.3. Market Revenue and Forecast, by Service
12.3.6.4. Market Revenue and Forecast, by Therapeutic Areas
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type
12.3.7.2. Market Revenue and Forecast, by Molecule Type
12.3.7.3. Market Revenue and Forecast, by Service
12.3.7.4. Market Revenue and Forecast, by Therapeutic Areas
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type
12.3.8.2. Market Revenue and Forecast, by Molecule Type
12.3.8.3. Market Revenue and Forecast, by Service
12.3.8.4. Market Revenue and Forecast, by Therapeutic Areas
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type
12.4.2. Market Revenue and Forecast, by Molecule Type
12.4.3. Market Revenue and Forecast, by Service
12.4.4. Market Revenue and Forecast, by Therapeutic Areas
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type
12.4.5.2. Market Revenue and Forecast, by Molecule Type
12.4.5.3. Market Revenue and Forecast, by Service
12.4.5.4. Market Revenue and Forecast, by Therapeutic Areas
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type
12.4.6.2. Market Revenue and Forecast, by Molecule Type
12.4.6.3. Market Revenue and Forecast, by Service
12.4.6.4. Market Revenue and Forecast, by Therapeutic Areas
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type
12.4.7.2. Market Revenue and Forecast, by Molecule Type
12.4.7.3. Market Revenue and Forecast, by Service
12.4.7.4. Market Revenue and Forecast, by Therapeutic Areas
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type
12.4.8.2. Market Revenue and Forecast, by Molecule Type
12.4.8.3. Market Revenue and Forecast, by Service
12.4.8.4. Market Revenue and Forecast, by Therapeutic Areas
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type
12.5.2. Market Revenue and Forecast, by Molecule Type
12.5.3. Market Revenue and Forecast, by Service
12.5.4. Market Revenue and Forecast, by Therapeutic Areas
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type
12.5.5.2. Market Revenue and Forecast, by Molecule Type
12.5.5.3. Market Revenue and Forecast, by Service
12.5.5.4. Market Revenue and Forecast, by Therapeutic Areas
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type
12.5.6.2. Market Revenue and Forecast, by Molecule Type
12.5.6.3. Market Revenue and Forecast, by Service
12.5.6.4. Market Revenue and Forecast, by Therapeutic Areas
13.1. Thermo Fisher Scientific Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Medpace
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. IQVIA
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. CTI Clinical Trial & Consulting
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Parexel International (MA) Corporation.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. ICON plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Laboratory Corporation of America Holdings
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. WuXi AppTec
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Veeda Clinical Research
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample